Ny bruk av gammelt antipsykotika?

Et gammelt avregistrert schizofreni-legemidel fra 50-tallet kan ha effekt på pasienter med hjernekreft.

CHICAGO: Tor-Christian Aase Johannessen, lege og postdoktor ved Institutt for Biomedisin ved Universitetet i Bergen (UiB), forsker på behandling av glioblastom, den hyppigst forekommende og mest dødelige formen for hjernekreft hos voksne. Den rammer rundt 250 personer hvert år i Norge. Les mer www.dagensmedisin.no.

Dr. Robert Kerbel visits the K.G. Jebsen BTRC

The K.G. Jebsen BTRC was one of the sponsors that supported a visit to Bergen (9-11 June, 2015) Dr. Robert Kerbel, a leading expert on angiogenesis. Dr. Kerbel is Professor in the Department of Medical Biophysics University of Toronto, Senior Scientist at the Sunnybrook Research Institute in Toronto, and a Canada Research Chair in Tumor Biology and Angiogenesis. He gave a top lecture “Antiangiogenic Therapeutics in Oncology: Overview, Update, and Future Directions”. After describing the main types of current antiangiogenic drug based therapies (over the last decade nine different antiangiogenic drugs has been approved for over ten different cancer indications), Dr. Kerbel analyzed possible causes of numerous  failures of phase III clinical trials that involved antiangiogenic drugs, and summarized the most promising strategies for improving the efficacy of antiangiogenic treatment. At the end of the talk Dr. Kerbel presented some of his personal studies. This fascinating lecture was followed by an impressive discussion covered a broad range of questions from some specific issues of antiangiogenic therapy and its promising combination with immunotherapy, to the general perspectives of winning the war against cancer.

As a part of his scientific program in Bergen Dr. Kerbel visited the K.G. Jebsen BTRC to meet the BTRC director Professor Rolf Bjerkvig, who presented an overview of the research activities of the center. The fruitful discussion was focused on the development of improved, more translationally relevant, preclinical therapy models of advanced metastatic disease for evaluating antiangiogenic drug mechanisms and efficacy. It led to an agreement on establishing collaboration between the K.G. Jebsen BTRC and the Kerbel laboratory.

Left panel: Dr. Robert Kerbel speaking at the seminar in the Dept. of Biomedicine at the University of Bergen. Right panel: Dr. Robert Kerbel (left side) having a discussion with Prof. Rolf Bjerkvig (right side). FOTO: Oleg Tsinkalovsky
Left panel: Dr. Robert Kerbel speaking at the seminar in the Dept. of Biomedicine at the University of Bergen. Right panel: Dr. Robert Kerbel (left side) having a discussion with Prof. Rolf Bjerkvig. FOTO: Oleg Tsinkalovsky

Oleg Tsinkalovsky, MD, PhD

Signing of an official collaboration agreement between KG Jebsen BTRC at UiB & Shandong University, China

The 8th of May, The University of Bergen and the KG-Jebsen BTRC, signed an official collaboration agreement with Shandong University, Qilu Hospital in China. The main purpose of this agreement is joint research programmes on brain tumours, with special emphasis on translational research. Continue reading Signing of an official collaboration agreement between KG Jebsen BTRC at UiB & Shandong University, China